About rafael holdings inc - RFL
Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. It operates through the following segments: Healthcare, Infusion Technology, and Real Estate. The Healthcare segment relates to the activities of LipoMedix, Barer, Farber, and Rafael Medical Devices. The Infusion Technology segment manages equity interest on Day Three. The Real Estate segment refers to the company’s real estate holdings. The company was founded in 2017 and is headquartered in Newark, NJ.
RFL At a Glance
Rafael Holdings, Inc.
520 Broad Street
Newark, New Jersey 07102
| Phone | 1-212-658-1450 | Revenue | 917.00K | |
| Industry | Real Estate Development | Net Income | -30,520,000.00 | |
| Sector | Finance | 2025 Sales Growth | 43.956% | |
| Fiscal Year-end | 07 / 2026 | Employees | 23 | |
| View SEC Filings |
RFL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 54.224 |
| Price to Book Ratio | 0.923 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.063 |
| Enterprise Value to Sales | 1.774 |
| Total Debt to Enterprise Value | 0.425 |
RFL Efficiency
| Revenue/Employee | 39,869.565 |
| Income Per Employee | -1,326,956.522 |
| Receivables Turnover | 0.50 |
| Total Asset Turnover | 0.009 |
RFL Liquidity
| Current Ratio | 4.889 |
| Quick Ratio | 4.865 |
| Cash Ratio | 4.549 |
RFL Profitability
| Gross Margin | 53.98 |
| Operating Margin | -2,847.219 |
| Pretax Margin | -3,620.065 |
| Net Margin | -3,328.244 |
| Return on Assets | -28.937 |
| Return on Equity | -34.569 |
| Return on Total Capital | -32.098 |
| Return on Invested Capital | -34.553 |
RFL Capital Structure
| Total Debt to Total Equity | 0.733 |
| Total Debt to Total Capital | 0.728 |
| Total Debt to Total Assets | 0.606 |
| Long-Term Debt to Equity | 0.083 |
| Long-Term Debt to Total Capital | 0.082 |